Tag: Payload
Unlocking the Potential of Antibody-drug Conjugates
One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He...
The Complexities of the ADC Design: What’s Needed to Improve the...
Antibodies serve an important function in the immune system by attaching to specific molecules, or antigens, on the surface of a foreign body, such...
Lonza Expands Manufacturing Capacity for ADC Payloads
Lonza, a specialty contract development and manufacturing (CDMO) partner to the biopharma industry, will add new highly potent API (HPAPI) manufacturing suites at its...
ADCs – The Dawn of a New Era?
Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.
Are Small-Format Drug Conjugates a Viable ADC Alternative Solid Tumors?
Antibody-drug conjugates or ADCs are complex immunoconjugates. They are designed to selectively deliver a small-molecules cytotoxic payload to cancer cells. Directed to specific tumor...
Antibody Drug Conjugate Development: Keys to Rapid IND Submission and Approval
Antibody drug conjugates (ADCs) are a relatively new type of drug that combines the targeting ability of a biologic with a highly potent cytotoxic...